Keliximab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameKeliximab
Drug Alias NameAnti-CD4 monoclonal antibody IDEC-CE9.1PRIMATIZED anti-CD4 antibody IDEC-CE9.1IDEC-CE9.1SB-210396
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionT-cell surface antigen CD4 inhibitors
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsAsthmaArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcBiogen Inc
Active IndicationsN/A
Inactive IndicationsAsthmaArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipedia